The plain-language read
Niacinamide (nicotinamide) is a water-soluble form of vitamin B3 that has demonstrated significant benefits in multiple skin conditions. Randomized controlled trials have shown 4% niacinamide significantly reduces sebum production, pore appearance, and hyperpigmentation.
- 4% niacinamide significantly reduces sebum production
- Inhibits melanin transfer reducing hyperpigmentation
- Enhances ceramide synthesis improving barrier function
- Well-tolerated across all skin types including sensitive
Use 4-5% niacinamide twice daily. Compatible with most actives. Particularly valuable for combination, oily, and hyperpigmentation-prone skin.
What this means for your routine
If you're targeting hyperpigmentation, this research supports adding niacinamide to your AM/PM routine. Effective concentration range: 4% based on this study. Timeline to expect: 4 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
Technical Summary, For Professional Reference
Clinical context
Niacinamide (nicotinamide) is a water-soluble form of vitamin B3 that has demonstrated significant benefits in multiple skin conditions. Randomized controlled trials have shown 4% niacinamide significantly reduces sebum production, pore appearance, and hyperpigmentation. The mechanism involves inhibition of melanosome transfer to keratinocytes, anti-inflammatory cytokine modulation, and enhanced ceramide synthesis.
Full abstract→
Niacinamide (nicotinamide) is a water-soluble form of vitamin B3 that has demonstrated significant benefits in multiple skin conditions. Randomized controlled trials have shown 4% niacinamide significantly reduces sebum production, pore appearance, and hyperpigmentation. The mechanism involves inhibition of melanosome transfer to keratinocytes, anti-inflammatory cytokine modulation, and enhanced ceramide synthesis. Studies demonstrate 5% concentrations improve skin barrier function within 4 weeks of twice-daily application.
Original source →Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.
Friedreich's ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low cardiopulmonary fitness. We tested the effect of exercise and NAD+ precursor supplementation with nicotinamide riboside, which have each shown benefits in animal and early clinical studies, on cardiopulmonary fitness in individuals with Friedreich's ataxia. This 12-week, outpatient, phase 2, single-site (Children's Hospital of Philadelphia, Philadelphia, PA, USA), randomised, 2 × 2 factorial clinical trial recruited individuals aged 10-40 years with an ejection fraction of 45% or greater who were able to exercise.
Multitargeted Modulation of Skin Dullness by HNHT Formulation: Synergistic Inhibition of Melanogenesis, Glycation, and Lipofuscin Deposition.
Skin dullness, characterized by pigmentation disorders and yellowing, is a major cosmetic concern in Asian populations. Lipofuscin exhibits ultraviolet (UV)/visible light spectral absorption, reduces skin reflectance, and contributes to dullness, whereas existing therapies targeting melanogenesis and glycation lack comprehensive efficacy. This study aimed to evaluate the multimodal anti-dullness effects of a novel formulation (HNHT: hyaluronic acid, niacinamide, hydrolyzed red algae, and tranexamic acid).
Changes in ultraviolet a radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial.
Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.